Rosen Law Firm Urges Ardelyx Investors to Act
Rosen Law Firm has urged Ardelyx, Inc. shareholders who purchased stock between January 13, 2025, and August 6, 2026, to consider legal action.
NEW YORK – Investors in Ardelyx, Inc. (NASDAQ: ARDX) who purchased shares between January 13, 2025, and August 6, 2026, have been urged by Rosen Law Firm to take action before the November 16, 2026, deadline.
The specified period relates to a class action lawsuit alleging misrepresentations regarding Ardelyx's commercial performance and growth prospects for its products XPHOZAH and IBSRELA. The complaint claims the company issued misleading statements and concealed material facts concerning payer access issues, stricter prior authorization requirements, and step edit requirements that slowed new patient starts and delayed prescription fulfillment.
Rosen Law Firm stated that investors who purchased Ardelyx stock during the specified period may be entitled to compensation without out-of-pocket fees. The firm has filed a class action lawsuit and encourages potential plaintiffs to seek legal counsel before the deadline.
According to the complaint, investors suffered damages when the true details entered the market. The law firm advises potential claimants to review the class action details and act promptly.